Form 4: Elicio Therapeutics Director and 10% Owner Acquires Warrants

Yekaterina Chudnovsky, a Director and 10% owner of Elicio Therapeutics, Inc., indirectly acquired 103,225 warrants to purchase common stock through GKCC, LLC.

Summary

• Yekaterina Chudnovsky, identified as a Director and 10% Owner of Elicio Therapeutics, Inc. (ELTX), reported a transaction on June 3, 2025.
• The transaction involved the acquisition of 103,225 derivative securities in the form of warrants, with an exercise price of $7.75 per share.
• These warrants are exercisable immediately from June 3, 2025, and have an expiration date of June 3, 2030.
• Each warrant grants the right to buy one share of Elicio Therapeutics Common Stock.
• The warrants were acquired at a price of $0 per derivative security, indicating they were likely granted or issued rather than purchased at a market price.
• The beneficial ownership of these warrants is indirect, held by GKCC, LLC, where Yekaterina Chudnovsky is the sole member and manager.

Sentiment

Score: 7

Explanation: The acquisition of warrants by a director and significant owner is generally viewed as a positive signal, indicating insider confidence in the company's future performance and potential stock price appreciation.

Positives

• The acquisition of 103,225 warrants by a director and significant owner (Yekaterina Chudnovsky) can be interpreted as a strong vote of confidence in Elicio Therapeutics' future prospects.
• Warrants typically gain value if the underlying stock price increases above the exercise price, suggesting the insider anticipates future stock appreciation.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's future financial performance or strategic direction.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specific to Elicio Therapeutics, Inc., and does not provide broader insights into industry trends or competitive landscape.

Related Party Transactions

• The acquisition of 103,225 warrants by GKCC, LLC, an entity controlled by Yekaterina Chudnovsky, who serves as a Director and 10% owner of Elicio Therapeutics, Inc., constitutes a related party transaction.

Stakeholder Impact

• Shareholders may perceive this insider acquisition as a positive indicator of management's belief in the company's future value, potentially boosting investor confidence.

Key Dates

Recommendation

Keywords

Elicio Therapeutics, ELTX, Form 4, insider transaction, beneficial ownership, warrants, derivative securities, Yekaterina Chudnovsky, GKCC LLC, director, 10% owner